Intensity Therapeutics financials
$3.42−6.30%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$12.0M | -$16.6M | -$8.3M | -$7.5M |
| Net income | -$11.6M | -$16.3M | -$11.9M | -$7.6M |
| Net margin | — | — | — | — |
| Diluted EPS | $-8.56 | $-29.24 | $-34.50 | $-55.50 |
| EBITDA | -$12.0M | -$16.6M | -$8.3M | -$7.4M |
| Operating cash flow | -$9.2M | -$15.2M | -$7.2M | -$5.5M |
| Free cash flow | -$9.2M | -$15.2M | -$7.2M | -$5.5M |
| Diluted shares | 1.4M | 0.6M | 0.3M | 0.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $11.9M | $2.6M | $8.6M | $1.3M |
| Short-term investments | $0.00 | $0.00 | $6.2M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $4.3M |
| Total assets | $14.1M | $4.8M | $17.3M | $1.8M |
| Total liabilities | $2.2M | $1.9M | $4.1M | $6.9M |
| Shareholders' equity | $11.9M | $2.9M | $13.2M | -$15.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology